BridgeMD
New treatment option for Solid Tumors
Official title A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
ClinicalTrials.gov ID: NCT06826313
What this study is testing
What is VRT106?
VRT106 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for solid tumors.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- people voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow...
- Males and females are aged at 18-75 years (including borderline values) at the time of signing the ICF, male or female.
- people are histologically or cytologically confirmed to be intolerable or refractory to the standard systemic treatment.
- people have at least one measurable lesion.
- ECOG score of 0 to 28 days prior to first dose of IMP.
You likely can't join if
- Subject has received any antitumor therapy within 4 weeks prior to the first dose of IMP.
- Subject has previously received oncolytic virus or other gene drug therapy.
- Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of IMP.
- Subject is known to have an allergic reaction to any of the components of IMP.
- Women who are breastfeeding.
See the full eligibility criteria
- people voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures.
- Males and females are aged at 18-75 years (including borderline values) at the time of signing the ICF, male or female.
- people are histologically or cytologically confirmed to be intolerable or refractory to the standard systemic treatment.
- people have at least one measurable lesion.
- ECOG score of 0 to 28 days prior to first dose of IMP.
- An expected survival time of ≥ 12 weeks.
- Have sufficient organ function.
- Female patients of childbearing potential with a negative serum pregnancy test within 7 days prior to first dose of study drug.
- people of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose.
- Subject has received any antitumor therapy within 4 weeks prior to the first dose of IMP.
- Subject has previously received oncolytic virus or other gene drug therapy.
- Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of IMP.
- Subject is known to have an allergic reaction to any of the components of IMP.
- Women who are breastfeeding.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.